Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Trial Details

NCT ID

NCT05894018

Phase

PHASE2

Sponsor

Fujun Zhang

Status

RECRUITING

Cancer Type

Sarcoma

Interventions

• Fluzoparib
• Radioactive particle implantation

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Voluntarily agree to participate in this study and sign an informed consent form;
• Age ≥18 (calculated on the day of signing the informed consent), regardless of gender;
• Pathologically confirmed soft tissue sarcoma, with at least one measurable lesion according to RECIST 1.1 criteria on CT or MRI scan, within 28 day…
• A single lesion ≤5cm and no more than 5 lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.